Shionogi & Co. Ltd (SGIOF PINK) stock market data APIs
$14.2406
0(0%)
as of October 20, 2025
Try our APIs with
free plan!
Shionogi & Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan.
Prev. Close
14.2406
Open
14.2406
High
14.2406
Low
14.2406
52 wk Range
11.4446-19
Market Cap
13 596 M
P/E Ratio
10.7143
Shares Outstanding
851 M
Revenue
440 495 M
EPS
0.3201
Dividends (Yield)
0.0315
Beta
0.126
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shionogi & Co. Ltd data using free add-ons & libraries
Get Shionogi & Co. Ltd Fundamental Data
Shionogi & Co. Ltd Fundamental data includes:
- Net Revenue: 440 495 M
- EBITDA: 184 653 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-28
- EPS/Forecast: 45.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shionogi & Co. Ltd News
New
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) i...
Roche’s Genentech launches DTC program amid Trump’s MFN directive
[Roche Diagnostics campus facade in Silicon Valley] Michael Vi/iStock Editorial via Getty Images Roche’s (OTCQX:RHHBY [https://seekingalpha.com/symbol/RHHBY]) Genentech unit on Thursday announced a...
Gareth Morgan Named President of Qpex Biopharma, Inc.
SAN DIEGO, October 15, 2025--(BUSINESS WIRE)--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter "Qpex"), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global H...
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults Sixty-...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
